Article Fingerprint
ReserarchID
LADA8
TTP is a very uncommon disease which used to have very high mortality and morbidity before the introduction of plasmapharesis and immunosup-pressant therapy. Even after the introduction of these modalities, atypical HUS patients had a very grave prognosis and ultimately led to death in many until the introduction of complement inhibitors like eculizumab which is C5a monoclonal antibody. Additionally differentiating typical HUS versus atypical HUS was very difficult but some work on complement markers can be very fruitful in differentiating them.
Ali Ghani. 2014. \u201cLatest Diagnostic and Treatment Modalities for TTP\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 14 (GJMR Volume 14 Issue F3): .
Crossref Journal DOI 10.17406/gjmra
Print ISSN 0975-5888
e-ISSN 2249-4618
Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.
Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.
Total Score: 132
Country: United States
Subject: Global Journal of Medical Research - F: Diseases
Authors: AliRaza Ghani, Ahsan Raza (PhD/Dr. count: 0)
View Count (all-time): 163
Total Views (Real + Logic): 4593
Total Downloads (simulated): 2298
Publish Date: 2014 09, Sat
Monthly Totals (Real + Logic):
This paper attempted to assess the attitudes of students in
Advances in technology have created the potential for a new
Inclusion has become a priority on the global educational agenda,
TTP is a very uncommon disease which used to have very high mortality and morbidity before the introduction of plasmapharesis and immunosup-pressant therapy. Even after the introduction of these modalities, atypical HUS patients had a very grave prognosis and ultimately led to death in many until the introduction of complement inhibitors like eculizumab which is C5a monoclonal antibody. Additionally differentiating typical HUS versus atypical HUS was very difficult but some work on complement markers can be very fruitful in differentiating them.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.